Intraperitoneal Chemotherapy Administration Prolongs Survival for Women With Advanced Ovarian Cancer
5th Jan 2006, 12:46 GMT
Findings Indicate That Expertise in Management of Intraperitoneal Catheters is an Important Issue in Administration of IP Chemotherapy
Intraperitoneal Chemotherapy Administration Prolongs Survival for Women With Advanced Ovarian Cancer related news:
- Intraperitoneal chemotherapy administration prolongs survival for women with advanced ovarian cancer — EurekAlert! - Breaking News
- New ovarian cancer regimen boosts survival — PittsburghLIVE.com
- Underutilized treatment for advanced ovarian cancer found to significantly improve survival — EurekAlert! - Breaking News
- New Chemotherapy Regimen Improves Survival for Advanced Ovarian Cancer Patients — Blogcritics
- Radical Therapy for Ovarian Cancer Boosting Survival ; Rigors of Treatment a Downside — RedOrbit News - Health
- Treatment Brings Hope for Ovarian Cancer (Associated Press) —
- New treatment touted to fight ovarian cancer — Chicago Sun-Times
- Treatment Brings Hope for Ovarian Cancer — Lancaster Online - Health
- Study Brings Big Advance Against Ovarian Cancer — KOMO - HealthWatch
- Delivering chemotherapy directly into the abdomen boosts survival in ovarian cancer patients — News-Medical News Feed
Latest news from Pharmaceuticals News from StratCenter.com:
- Spectrum Pharmaceuticals to Receive $5 mln Milestone Payment From PAR Pharmaceutical for Sumatriptan Injection
- Medco to Present at the Credit Suisse Annual Healthcare Conference
- Bob Dole Medicare Podcast Helps Seniors through 2007 Drug Coverage Enrollment Process
- Unique Sugar Improves Energy, Pain and Quality of Life in Fibromyalgia and Chronic Fatigue Patients!
- Care Clinic Purchases Pinnacle Easy Care
- Pegasystems Enhances 2 Business Critical BPM Frameworks for the Healthcare Industry
- Isis Cholesterol Drug Shown Effective
- Taro Receives Marketing Authorization in UK for Etopan XL Tablets 600 mg, Etodolac
- Nymox Reports Q3 2006 Financial Results
- RemoteMDx Raises $6 mln in Private Placement